 |
|
|
|
 |
|
|
| Article 1 to 10 out of 38 concerning Biovitrum AB
|
-
Biovitrum Implements Strategic Restructuring of the R&D Organization
(19 May 2008)
Running R&D expenses estimated to be reduced by MSEK 115 on a rolling twelve-month basis
Biovitrum AB announced that it has completed the review of its research and development organization as announced in November 2007, when the company's new business strategy was initiated. In the new strategy, Biovitrum will focus on specialist care ...
-
Biovitrum and Symphogen Initiates a Second Clinical study with a Novel Treatment of Hemolytic Diseases
(21 Apr 2008)
Biovitrum AB and Symphogen A/Sannounced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation of RhD-negative healthy ...
-
First premature infant recruited in Kiobrina study
(07 Apr 2008)
Triggers milestone payment from Biovitrum
Biovitrum AB is in clinical phase II with the Kiobrina project and the first preterm infant has been recruited. This triggers a milestone payment from Biovitrum.Kiobrina(TM) is a recombinant, biotechnically produced human enzyme (BSSL) that breaks ...
-
Peter Edman new Chief Scientific Officer at Biovitrum AB
(28 Mar 2008)
Peter Edman, PhD, Associate Professor, 54, will join Biovitrum as Chief Scientific Officer. He is leaving his current position as Vice President and Global Project Director, Global Development, at AstraZeneca.Peter Edman has previously held a number ...
-
Biovitrum and Syntonix begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for treatment of Hemophilia B
(06 Mar 2008)
Biovitrum AB and Syntonix Pharmaceuticals, Inc. have obtained approval from the US Food and Drug Administration to commence a clinical phase I/IIa study of a long-acting, recombinant Factor IXFc for the treatment of Hemophilia B.The US Food and Drug ...
-
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma
(15 Feb 2008)
Biovitrum has completed a first explorative clinical Phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist intended for the treatment of glaucoma. The preliminary results show a dose dependent reduction of the intraocular pressure; a ...
-
Biovitrum Makes the First Move to Focus on Specialist Care Diseases
(08 Feb 2008)
Initiates the Process to Find Partners for Its Early Stage Primary Care Projects
In November 2007, the management of the Swedish biopharma company Biovitrum announced a new strategy for creating long-term value and turning Biovitrum into a focused pharmaceutical company concentrated on specialist care projects. As a consequence ...
-
Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
(07 Feb 2008)
Biovitrum and Symphogen announced the completion of a phase I clinical trial to test the safety and tolerability of Sym001 in healthy volunteers. The results from the dose-escalation, placebo-controlled study show that Sym001 is well tolerated.Sym001...
-
Biovitrum has Successfully Completed the First Phase I Trial of its 5-HT6 Receptor Antagonist (BVT.74316)
(21 Dec 2007)
A clinical phase I trial of BVT.74316 has now been successfully completed. This first clinical study, with the objective to test safety and tolerability in escalating single-dose and repeated-dose administration was started in August 2006. In total, ...
-
Results from Biovitrum's Phase II Clinical Trial of Novel Pain Treatment
(14 Dec 2007)
Biovitrum evaluates a novel method for treating pain in a phase II clinical trial. The recruitment of patients to the study has now been completed and the results are expected to be presented already early second quarter 2008.The treatment aims at ...
Additional information
Biovitrum AB
Stockholm, Sweden
Company
|
|
|
|
|
|
Top
